Sullivan Christopher Ryan
SEC CIK 1810417 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| AVTX | Avalo Therapeutics, Inc. | CFO | 52.3K | $3,247 | $3.72M | 21 | 2021-12-10 | 2026-09-16 |
Most active insiders at AVTX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Sullivan Christopher Ryan | CFO | — | $3.72M |
| 2 | Doyle Mittie | Chief Medical Off | — | $2.98M |
| 3 | VARKI PAUL | CLO | — | $1.51M |
| 4 | Goldman Jonathan | Dir | — | $163.0K |
| 5 | Chan Mitchell | Dir | — | $72.5K |
| 6 | Riley Jennifer | Chief Strategy Off | — | $52.0K |
| 7 | Truex Samantha | Dir | — | — |
| 8 | KANTOFF AARON | Dir | — | — |
| 9 | NEIL GARRY ARTHUR | CEO, Dir | — | — |
| 10 | KAPLAN GILLA | Dir | — | — |
Transactions 21
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-09-18 16:10 | 2026-09-16 | AVTX | Avalo Therapeutics, Inc. | Sullivan Christopher Ryan | CFO | M - OptEx | $9.88 | +12.4K | 52.3K | +31% | +$122.5K |
| DT | 2026-09-18 16:10 | 2026-09-16 | AVTX | Avalo Therapeutics, Inc. | Sullivan Christopher Ryan | CFO | S - Sale+OE | $16.33 | -12.4K | 39.9K | -24% | -$202.4K |
| DT | 2026-09-11 16:10 | 2026-09-10 | AVTX | Avalo Therapeutics, Inc. | Sullivan Christopher Ryan | CFO | M - OptEx | $8.04 | +10.2K | 50.1K | +26% | +$81.9K |
| DT | 2026-09-11 16:10 | 2026-09-10 | AVTX | Avalo Therapeutics, Inc. | Sullivan Christopher Ryan | CFO | S - Sale+OE | $17.62 | -10.2K | 39.9K | -20% | -$179.5K |
| DMT | 2026-08-19 16:10 | 2026-08-17+ | AVTX | Avalo Therapeutics, Inc. | Sullivan Christopher Ryan | CFO | M - OptEx | $9.88 | +71.9K | 70.9K | New | +$709.9K |
| DMT | 2026-08-19 16:10 | 2026-08-17+ | AVTX | Avalo Therapeutics, Inc. | Sullivan Christopher Ryan | CFO | S - Sale+OE | $19.94 | -72.7K | 39.9K | -65% | -$1.45M |
| 2026-06-12 16:36 | 2026-06-10 | AVTX | Avalo Therapeutics, Inc. | Sullivan Christopher Ryan | CFO | F - Tax | $13.10 | -138 | 40.8K | -0.3% | -$1,808 | |
| 2026-05-26 16:10 | 2026-05-21 | AVTX | Avalo Therapeutics, Inc. | Sullivan Christopher Ryan | CFO | A - Grant | $0.00 | +39.9K | 40.3K | +9,433% | $0 | |
| DT | 2026-05-11 16:05 | 2026-05-07 | AVTX | Avalo Therapeutics, Inc. | Sullivan Christopher Ryan | CFO | M - OptEx | $9.88 | +18.6K | 19.0K | +4,399% | +$183.8K |
| DT | 2026-05-11 16:05 | 2026-05-07 | AVTX | Avalo Therapeutics, Inc. | Sullivan Christopher Ryan | CFO | S - Sale+OE | $24.12 | -18.6K | 423 | -98% | -$448.8K |
| DT | 2026-05-07 16:16 | 2026-05-06 | AVTX | Avalo Therapeutics, Inc. | Sullivan Christopher Ryan | CFO | M - OptEx | $8.04 | +47.0K | 47.4K | +11,111% | +$377.9K |
| DMT | 2026-05-07 16:16 | 2026-05-06 | AVTX | Avalo Therapeutics, Inc. | Sullivan Christopher Ryan | CFO | S - Sale+OE | $20.19 | -47.0K | 423 | -99% | -$948.7K |
| MT | 2026-05-01 16:37 | 2026-04-29+ | AVTX | Avalo Therapeutics, Inc. | Sullivan Christopher Ryan | CFO | S - Sale | $13.16 | -16.9K | 423 | -98% | -$222.6K |
| MT | 2026-04-03 15:14 | 2026-04-01+ | AVTX | Avalo Therapeutics, Inc. | Sullivan Christopher Ryan | CFO | S - Sale | $16.96 | -16.0K | 17.3K | -48% | -$270.6K |
| D | 2026-03-31 | 2026-03-28 | AVTX | Avalo Therapeutics, Inc. | Sullivan Christopher Ryan | CFO | F - Tax | $13.89 | -8,241 | 33.3K | -20% | -$114.5K |
| D | 2026-03-31 | 2026-03-28 | AVTX | Avalo Therapeutics, Inc. | Sullivan Christopher Ryan | CFO | M - OptEx | — | +24.2K | 41.5K | +140% | — |
| 2025-12-12 | 2025-12-10 | AVTX | Avalo Therapeutics, Inc. | Sullivan Christopher Ryan | CFO | F - Tax | $4.10 | -155 | 17.3K | -0.9% | -$635.50 | |
| D | 2025-04-01 | 2025-03-28 | AVTX | Avalo Therapeutics, Inc. | Sullivan Christopher Ryan | CFO | F - Tax | $8.46 | -7,285 | 16.9K | -30% | -$61.6K |
| D | 2025-04-01 | 2025-03-28 | AVTX | Avalo Therapeutics, Inc. | Sullivan Christopher Ryan | CFO | M - OptEx | — | +24.2K | 24.2K | +403,333% | — |
| 2023-06-13 | 2023-06-09 | AVTX | Avalo Therapeutics, Inc. | Sullivan Christopher Ryan | CFO | P - Purchase | $3.42 | +511 | 1,262 | +68% | +$1,748 | |
| 2021-12-14 | 2021-12-10 | AVTX | Avalo Therapeutics, Inc. | Sullivan Christopher Ryan | CAO | P - Purchase | $1.57 | +955 | 9,004 | +12% | +$1,499 |
Purchase Sale Sale after option exercise All abbreviations